Elicio Therapeutics, Inc. (ELTX)
NASDAQ: ELTX · Real-Time Price · USD
11.80
+0.37 (3.24%)
Aug 22, 2025, 4:00 PM - Market closed
Elicio Therapeutics Employees
Elicio Therapeutics had 32 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
32
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,706,625
Market Cap
192.62M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 32 | 0 | - |
Dec 31, 2023 | 32 | 9 | 39.13% |
Dec 31, 2022 | 23 | -1 | -4.17% |
Dec 31, 2021 | 24 | 2 | 9.09% |
Dec 31, 2020 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
ELTX News
- 12 days ago - Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients - GlobeNewsWire
- 17 days ago - Elicio Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 19 days ago - Elicio Therapeutics Announces Positive Recommendation by IDMC to Continue ELI-002 7P Randomized Phase 2 Study in Pancreatic Cancer Without Modifications to Final Analysis - GlobeNewsWire
- 2 months ago - Elicio Therapeutics to Host Virtual KOL Event on June 25, 2025 to Discuss AMP-Powered ELI-002 for the Treatment of KRAS mutation-driven Pancreatic Cancer - GlobeNewsWire
- 2 months ago - Elicio Therapeutics Secures $10 Million in Financing - GlobeNewsWire
- 3 months ago - Elicio Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 4 months ago - Elicio Therapeutics Reports Inducement Grant to New Chief Strategy and Financial Officer and Other New Hires - GlobeNewsWire
- 5 months ago - Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewsWire